HEALTH PROFESSIONAL · SOURCE READING

Lenalidomide (with or without rituximab)

Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Recurrent or Refractory Chronic Lymphocytic Leukemia / Treatment Options for Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL)

Lenalidomide is an oral immunomodulatory agent with response rates of more than 50%, with or without rituximab, for patients with previously treated and untreated disease.[16-22][Level of evidence C3] Prolonged, lower-dose approaches and attention to prevention of tumor lysis syndrome are suggested with this agent.[16,23] Combination therapy and long-term toxicities from using lenalidomide (such as increased myelodysplasia, as seen in myeloma patients) remain undefined for patients with CLL.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice